24/7 Market News Snapshot 12 March, 2025 – OptimizeRx Corporation Common Stock (NASDAQ:OPRX)

March 12, 2025

DENVER, Colo., 12 March, 2025 (247marketnews.com) – (NASDAQ:OPRX) are discussed in this article.
OptimizeRx Corporation has experienced a significant surge in its stock price, opening at $4.85 and rising to $6.34, representing an impressive increase of over 53%. This bullish momentum follows a prior close of $4.14, indicating strong market interest and confidence. With a trading volume of 2.36 million shares, technical indicators suggest an ongoing upward trend, making OptimizeRx an appealing prospect for both short-term traders and long-term investors within the healthcare technology sector.

In conjunction with this rising stock value, OptimizeRx has announced robust financial results for the fourth quarter and the full year ending December 31, 2024. The Company reported fourth-quarter revenues of $32.3 million, reflecting a 14% year-over-year increase, and a full-year revenue increase of 29%, totaling $92.1 million. Gross profits for Q4 also saw a notable rise of 23%, reaching $22.0 million, which corresponds to a strong gross margin of 68%. These figures underscore OptimizeRx’s position as a leader in healthcare technology, bolstered by its innovative approaches to addressing key challenges faced by pharmaceutical companies.

CEO Stephen L. Silvestro highlighted the significant momentum that has contributed to these results, particularly through the expansion of the Dynamic Audience Activation Platform (DAAP). The number of revenue-generating collaborations has doubled from 24 in the previous year to 48 in 2024, demonstrating heightened engagement and relevance in a fast-evolving healthcare landscape.

Moving forward, OptimizeRx aims to achieve at least $100 million in revenue and an Adjusted EBITDA of $12 million by 2025. The Company’s strategic focus on enhancing customer relations through a subscription-based model, coupled with its commitment to operational excellence, positions it favorably for sustainable growth and increased shareholder value in the forthcoming fiscal year. This dedication to innovation in healthcare is set to enhance patient access to crucial therapies and solutions.

Related news for (OPRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.